U.S. Opioid and Non-Opioid Pain Management Pharmaceuticals Markets

Published by: Frost & Sullivan

Published: Feb. 26, 2007 - 87 Pages

Table of Contents

1. Executive Summary

1. Executive Summary

1. Executive Summary

2. Total U.S. Opioid and Non-Opioid Pain Management Pharmaceuticals Markets

1. Market Overview

1. Introduction

2. Scope and Segmentation

3. Research Methodology

4. Market Engineering Measurements

2. Market Forecasts

1. Patient Forecasts

2. Pricing Forecasts

3. Revenue Forecasts

3. Competitive Analysis

1. Market Share Analysis

2. Product Pipeline

3. U.S. Opioid Pain Management Pharmaceuticals Market

1. Market Overview

1. Introduction

2. Market Engineering Measurements

2. Market Forecasts

1. Patient Forecasts

2. Pricing Forecasts

3. Revenue Forecasts

3. Competitive Analysis

1. Competitive Structure

2. Market Share Analysis

4. U.S. Non-Opioid Pain Management Pharmaceuticals Market

1. Market Overview

1. Introduction

2. Market Engineering Measurements

2. Market Forecasts

1. Patient Forecasts

2. Pricing Forecasts

3. Revenue Forecasts

3. Competitive Analysis

1. Competitive Structure

2. Market Share Analysis

5. Decision Support Databases

1. Disease Incidence

1. Arthritis Prevalence

2. Demographic Indicators

1. Population Above 65

2. Percent of Population Above 65

3. Male Population Above 65

4. Female Population Above 65

3. Market Indicator

1. OTC as Percent of Total Pharma

Abstract

This Frost & Sullivan research service titled U.S. Opioid and Non-opioid Pain Management Pharmaceuticals Markets provides a detailed analysis of the competitive structure, market forecasts, and market share. In this study, Frost & Sullivan's expert analysts thoroughly examine the following markets: Opioid and non-opioid pain management pharmaceuticals.

Market Overview

Partnerships between Specialty Pharmaceutical and Drug Delivery Companies to Help Improve Therapies for Opioid and Non-Opioid Pain Management

The significant recall of Vioxx and Bextra from the market, coupled with the robust demand for pain management therapies, is creating substantial opportunities for novel therapies in the U.S. opioid and non-opioid pain management markets. Despite the lack of major breakthrough therapies, specialty pharma and drug delivery companies have successfully engaged in lifecycle management partnerships to relaunch older therapies in newer formulations to cater to the swelling demand.

"A rapidly ageing population is substantially driving the need for effective pain management therapies for acute and chronic pain," says the analyst of this research service. "There is considerable unmet medical need in the treatment of pain and newer and more effective therapies will be welcome in this market." Noting the remarkable market potential, several "Big Pharma", specialty pharmaceutical, and drug delivery companies have been planning to expand their market presence, thereby driving market growth.

Drug Delivery Companies to Promote Abuse-proof Formulations to Gain Wider Customer Acceptance and Meet Regulatory Norms

There have been increasing apprehensions regarding the safety profile of opioid and non-opioid therapies. The escalating regulatory and media scrutiny on opioid therapies have compelled drug companies to address the issue of potential drug abuse. "The collaborations between pharmaceuticals and drug delivery companies have ensured that next-generation drugs have abuse- and tamper-resistant formulations," notes the analyst. Market participants can promote this benefit to not only expand their customer base but also meet the increasingly stringent regulatory norms.

Get Full Details About This Report >>

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 250,000 market research reports, company profiles and country profiles from over 650 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.